SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Caladrius Biosciences, Inc. Merger

Wilmington, Delaware–(Newsfile Corp. – April 29, 2022) – Rigrodsky Law, P.A. is investigating Caladrius Biosciences, Inc. (“Caladrius”) (NASDAQ: CLBS) regarding possible breaches of fiduciary duties and other violations of law related to Caladrius’ agreement to merge with Cend Therapeutics, Inc.

To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-caladrius-biosciences-inc.

To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email [email protected].

Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.

Attorney advertising. Prior results do not guarantee a similar outcome.

Contact:
Rigrodsky Law, P.A.
Seth D. Rigrodsky, Esq.
Gina M. Serra, Esq.
Call or Text: (302) 295-5310
Email: [email protected]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/122227